Moreover, mutations in KRAS, a major driver mutation of non-small cell lung cancer (NSCLC), are correlated with elevated pro-inflammatory conditions, which favor the immune-suppressive microenvironment [32,223]. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.